MedTrace Logo

Effect of Dapagliflozin on Glycemic Variability

NCT02459353 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2017-07-13

No results posted yet for this study

Summary

Dapagliflozin improves glycemic variability in subjects with type 2 diabetes mellitus when added to insulin therapy. The primary objective of this study is to assess the effect of dapagliflozin on glucose variability compared to placebo after 12 weeks of treatment in type 2 diabetic patients with inadequate glycemic control on insulin.

Conditions

Interventions

DRUG

Dapagliflozin

DRUG

Placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Severance Hospital

    collaborator OTHER

  • Eulji General Hospital

    collaborator OTHER

  • Kyung Hee University Hospital at Gangdong

    collaborator OTHER

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Kun-Ho Yoon, Ph.D. · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-12-31
Completion
2017-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02459353 on ClinicalTrials.gov